Vera Therapeutics Inc Cl A VERA

$27.99 -1.06 (-3.65%)

Valuation

Market cap
2,017,044,000
Revenue TTM
$0
Net income TTM
$-299,610,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.18

Trading

Volume
1,982,000
Avg volume
2,228,610
Day's range
$27.46 – $29.44
Shares out
72,063,000
Stochastic %K
30%
Beta
1.06
Analysts
Strong Sell
Price target
$71.62

Price

Company profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluat...

Show more

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 770 0077
Website
https://veratx.com
Address
2000 Sierra Point Parkway, Suite 1200, Brisbane, United States

Latest news

Stocktwits

Merlintrader Oct 25, 9:19 PM
$VERA fell 3.6% to $27.99, below the 50-day EMA ($31.69) and the 200-day ($34.93), in the lower part of a 20-day range of $26.38-$33.60. Daily RSI 41. Interactive chart at JC Just Charts: https://justcharts.merlintrader.com/#VERA Not investment advice.
0 replies
EBE_day Oct 25, 4:26 PM
$VERA PIONEER featured positive interim safety and efficacy data for their dual BAFF and APRIL inhibitor, atacicept (TRUTAKNA). The data covered two major patient populations https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4592254
1 replies
TKkamen Oct 23, 11:01 AM
$VERA So apparently people were selling the stock today because the event risk reductions that were reported by of 76% was lower than Otsuka's 97% (and ignoring that their hematuria rates were better). Except the people selling failed to realize the two values had different methodologies and when you adjust for them, they look essentially equivalent. Does no one do any actual work anymore? Or is it just "A less than B, sell sell sell"? What's the point of hiring all these overly-educated analysts if your analytical effectiveness is equivalent to a boiled potato?
3 replies
treadingw4ter Oct 22, 9:03 PM
$VERA so.. what do we think??
2 replies
CH_Expat Oct 22, 7:01 PM
$VERA The YTD slaughtery is really something else.
0 replies
Theobviouschoice Oct 22, 4:57 PM
$VERA One word for you to remember PIONEER over the coming weekend🚀🚀🚀
0 replies
AXLFI_HQ Oct 21, 11:02 PM
The most recent Sustained Momentum signal on $VERA triggered on 2026-10-21. The expected return for the selected horizon is +27.33% with a historical profit probability of +58.33%. Learn more: https://axlfi.com/factors/stock/VERA/sus_momentum/daily
0 replies
JamesPond007 Oct 21, 10:53 PM
$VERA the time has come. 102 week data tomorrow
0 replies